Lietuvos sveikatos mokslu universiteto ligonine Kauno klinikos
- Address
- lock Available on a paid plan
Oncology & Hematologic Malignancies
At Lietuvos sveikatos mokslu universiteto ligonine Kauno klinikos, investigators are evaluating innovative treatments for a broad spectrum of cancers and blood disorders, with the goal of extending survival and preserving quality of life.
- Advanced melanoma and non‑small cell lung cancer
- Acute myeloid leukemia and myelodysplastic syndromes
- Prostate and bladder cancer
- Gastric and esophageal cancers
- Head and neck squamous cell carcinoma
- Renal cell carcinoma
- Myelofibrosis and other hematologic malignancies
These trials focus on testing targeted agents, immunotherapies, and combination regimens to assess safety and effectiveness.
Cardiovascular & Metabolic Disorders
Researchers conduct clinical trials on heart disease, hypertension, and metabolic conditions, aiming to lower cardiovascular risk and protect kidney function.
- Atherosclerotic cardiovascular disease and heart failure
- Chronic kidney disease with proteinuria
- Type 2 diabetes inadequately controlled
- LDL‑C and triglyceride‑lowering therapies
- Thromboembolic prevention after orthopedic surgery
- Cardiovascular outcomes with novel lipid‑lowering agents
The studies evaluate whether new medications can reduce heart attacks, strokes, or progression of renal impairment.
Autoimmune & Inflammatory Diseases
The department explores immune‑mediated conditions, seeking durable remission while minimizing adverse effects.
- Crohn’s disease and ulcerative colitis
- Rheumatoid arthritis and psoriatic arthritis
- Hidradenitis suppurativa and atopic dermatitis
- Systemic sclerosis and lupus nephritis
- Relapsing‑multiple sclerosis
- Immune thrombocytopenia and chronic urticaria
Trials often compare novel biologics or small molecules with standard care to determine efficacy and safety.
Neurology & Neurodegenerative Conditions
Clinical research targets disorders of the nervous system, focusing on disease‑modifying strategies and symptom control.
- Relapsing‑multiple sclerosis and secondary progressive MS
- Migraine prevention
- Neurogenic detrusor overactivity
- Neuro‑imaging biomarkers in MS
- Neuro‑inflammation in multiple sclerosis
- Neuro‑vascular complications after stroke
These studies assess long‑term safety of disease‑modifying therapies and their impact on disability progression.
Respiratory & Infectious Diseases
The site evaluates therapies for lung infections and chronic respiratory illnesses, aiming to reduce exacerbations and improve pulmonary function.
- Acute respiratory distress syndrome (ARDS)
- Chronic obstructive pulmonary disease (COPD)
- Community‑acquired pneumonia and COVID‑19
- Bronchiectasis
- Complicated urinary tract infections (as an infectious focus)
- Bacterial skin and soft‑tissue infections
Research includes antimicrobial agents and anti‑inflammatory drugs to shorten hospital stays and prevent complications.
Dermatology & Skin Disorders
Studies address both common and severe skin conditions, testing innovative biologics and small‑molecule inhibitors.
- Atopic dermatitis
- Chronic spontaneous urticaria
- Psoriasis and psoriatic arthritis
- Hidradenitis suppurativa
- Neovascular age‑related macular degeneration (ocular but related skin)
- Skin involvement in systemic diseases
The aim is to achieve rapid symptom relief and durable skin clearance with improved safety profiles.
Pediatric Growth & Endocrine Disorders
Research includes growth disorders in children, evaluating hormone therapies to support normal development.
- Short stature due to Turner syndrome or small for gestational age
- Growth hormone deficiency
- Acquired antithrombin deficiency affecting surgery
- Hormonal regulation in metabolic disease
- Bone health in chronic kidney disease
- Endocrine aspects of rare genetic syndromes
Trials compare weekly versus daily growth hormone regimens to determine optimal height velocity and safety.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 21 therapeutic areas and 15 of 281 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 268 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 35 by active trials.
lock +34 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG12trials
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 79 other sites in Lithuania
Therapeutic Area Benchmark — Lithuania
Select a therapeutic area to compare against other sites in Lithuania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Lithuania
Market Share
Country: Lithuania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lietuvos sveikatos mokslu universiteto ligonine Kauno klinikos
lock Showing 1 of 135 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 281 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 11 | Unknown | 2018-03-21 | 2025-07-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.